Tonsil-Derived Mesenchymal Stem Cell-Derived Small Extracellular Vesicles (sEVs) Restore Myo-Inositol Production in...

Area of Science:

• Cell Biology
• Stem Cell Biology
• Metabolic Research

Background:

• Systemic inflammation from lipopolysaccharide (LPS) impacts intestinal barrier integrity.
• Menopausal women face increased risks of chronic inflammation and metabolic syndrome.
• Myo-inositol supplementation benefits metabolic profiles in menopausal women.

Purpose of the Study:

• To investigate if T-MSC-derived sEVs can restore myo-inositol levels.
• To determine if T-MSC-derived sEVs promote myo-inositol synthesis in skeletal muscle.
• To assess T-MSC-derived sEVs efficacy in an LPS-induced inflammation model relevant to menopause.

Main Methods:

• Mice received repeated LPS administration over two weeks, with one group also receiving T-MSC-derived sEVs.
• Serum and skeletal muscle myo-inositol levels were measured post-treatment.
• In vitro studies assessed myo-inositol expression in LPS-treated muscle cells with and without T-MSC sEVs.

Main Results:

• T-MSC-derived sEVs significantly increased serum myo-inositol levels in LPS-exposed mice.
• Enhanced expression of myo-inositol synthesis proteins was observed in skeletal muscle.
• T-MSC sEVs treatment restored myo-inositol expression in LPS-treated myotubes.

Conclusions:

• T-MSC-derived sEVs show promise for treating intestinal leakage and inflammation in menopausal women.
• These sEVs may help maintain myo-inositol levels and improve skeletal muscle mass.
• Potential therapeutic strategy for menopause-associated metabolic disturbances.